FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women

This study is currently Recruiting

August 2011 By National Institute of Allergy and Infectious Diseases (NIAID)

First Recieved on October 28, 2010

Last Updated on November 3, 2011

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
Identifier: NCT01230814

Purpose

This research study is about vaginal infections such as bacterial vaginosis, yeast infections, and trichomoniasis. Usually, these infections can be treated with medication, but sometimes they come back after treatment. Researchers want to know if using vaginal suppositories can decrease the risk of vaginal infections. Participants will include 234 women who are sexually active (greater than or equal to 4 episodes of sex with men during the past month), HIV-negative, 18 to 45 years old, with bacterial infection [vaginosis and/or vulvovaginal candidiasis (VVC) and/or Trichomonas vaginalis] detected by laboratory testing at a screening visit. Women will receive vaginal suppositories containing drug or inactive ingredients (placebo). Participation in the study will be about 12 months. Study procedures include: urine and blood tests, physical exams, and questionnaires.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Eligibility

Ages Eligible for Study:18 Years
Genders Eligible for Study:Female
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: - Informed consent obtained and informed consent form (ICF) signed. - Female, aged 18-45 years. - Sexually active with greater than or equal to 4 episodes of sex with a male partner during the past month. - Human immunodeficiency virus (HIV)-seronegative on both HIV tests in parallel screening. - Presence of bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) and/or T. vaginalis infection at screening: 1. BV: Microscopic criteria (Nugent's score greater than or equal to 7) 2. VVC: Fungal elements (pseudohyphae, blastoconidia, or both) on vaginal saline wet mount plus a positive culture showing yeast on Sabouraud's agar. 3. T. vaginalis infection: Identification of motile trichomonads on vaginal saline wet preparation. - Able and willing to comply with study visit schedule and procedures during the 12-month period of follow-up. - Able and willing to abstain from sex or to use non-latex condoms (provided) for 24 hours following insertion of each vaginal suppository. - Willing to abstain from alcohol during, and for 48 hours after, treatment. - Plan to remain in study area for the next year. - Agree to not participate in other research studies involving drugs, medical devices, or vaginal products for the duration of study. Exclusion Criteria: - Currently pregnant (positive urine Beta-Human Chorionic Gonadotropin (hCG) or planning to conceive during the next 12 months (by self-report). - Currently breastfeeding. - Within first 3 months post-partum. - Current menstruation - women who are currently menstruating may be enrolled following the completion of menses. - History of 4 or more episodes of treatment for any vaginal infection in the past 12 months. This would be a cumulative total, including any treatment for bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) and/or Trichomonas vaginalis (TV) and/or syndromic. - History of medical condition that would contraindicate use of the study product 1. Porphyria 2. Epilepsy 3. Serious liver disease or signs and symptoms consistent with serious liver disease including jaundice, ascites, esophageal varices, encephalopathy, and bleeding disorders. 4. Renal failure - History of adverse reaction to the study medications (intravaginal metronidazole or miconazole). - Current use of medication that may interact with the study drug (due to vaginal absorption of study drug) 1. Warfarin 2. Phenytoin 3. Phenobarbital 4. Disulfiram 5. Cimetidine 6. Lithium 7. Astemizole 8. Terfenadine - Current use of oral or intravaginal antifungal medication. - Current use of oral or intravaginal metronidazole, tinidazole, or clindamycin. - Current use of latex diaphragm. - As determined by the investigator, a medical condition or situation exists such that study participation would not be advisable.

Investigators

Locations

  • Personal Health Clinic, University of Alabama at Birmingham

    Birmingham, Alabama 35294-0007 United States

  • Mombasa HIV/STD Research Site

    Mombasa, 00000 Kenya

  • Kenya AIDS Control Project, University of Nairobi

    Nairobi, 99999 Kenya

  • Kenya AIDS Vaccine Initiative, University of Nairobi

    Nairobi, 99999 Kenya

Conditions related to this trial:

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.